Phase II sbir - 80NSSC25C0036 nvasive: an AI and machine learning approach for metastasis prediction using nvasive and microgravity
Active Definitive Contract Awarded Last action
- Contract number
- 80NSSC25C0036
- Awardee
-
Encapsulate Inc. UEI JKQNFNJWF175
- Awarding agency
-
Shared Services Center
National Aeronautics and Space Administration
- Obligated
- $899,787
Award facts
- Contract value 100% obligated
- $899,787.00 Current and potential, with all options
- Completion date 65% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 500 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Farmington, CT 06032, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $899,787 |
About this award
Encapsulate Inc., a Farmington, Connecticut-based small disadvantaged business, has been awarded an $899,787 Phase II Small Business Innovation Research (SBIR) contract by the NASA Shared Services Center. The definitive contract, designated as a total small business set-aside with firm fixed pricing, extends through July 15, 2027. Under the NVASIVE project, Encapsulate Inc. will advance artificial intelligence and machine learning methodologies to predict cancer metastasis using noninvasive techniques and microgravity research environments. The Phase II effort builds on the company's Phase I contract (valued at $156,494 and completed in early 2025) and represents continued federal investment in the company's precision oncology platform.
The contract supports the development of automated microfluidic biochip platforms integrated with bioreactors and 3D tumor models, enabling patient-specific drug response prediction for cancer treatment applications. The work will be performed at Encapsulate's Farmington facility and focuses on creating scalable diagnostic technologies that test patient-derived cancer cells against chemotherapy drugs to enable personalized treatment selection prior to therapy initiation. This Phase II award is part of a broader federal investment in Encapsulate Inc. exceeding $5.3 million, including complementary funding from the National Science Foundation, validating the company's approach to addressing the estimated $2 billion domestic market opportunity in colorectal and pancreatic cancer treatment.
Quick answers
Who was awarded contract 80NSSC25C0036?
80NSSC25C0036 was awarded to Encapsulate Inc. by Shared Services Center (National Aeronautics and Space Administration) on July 16, 2025.
How much is contract 80NSSC25C0036 worth?
The government has obligated $899,787 on 80NSSC25C0036.
Was contract 80NSSC25C0036 competed?
The extent of competition for 80NSSC25C0036 was full and open competition after exclusion of sources. The government received 500 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award